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a  b  s  t  r  a  c  t
The  involvement  of the  central  nervous  system  in  dengue  infections  has  been  reported  in countries
where  the  disease  in  endemic.  The purpose  of  this  study  was  to  determine  whether  an  enzyme-linked
immunosorbent  assay  kit designed  to detect  the dengue  NS1  antigen  in  serum  was  able  to  detect  this
antigen  in  cerebral  spinal  ﬂuid  (CSF)  samples  from  patients  with  fatal  outcomes.  To evaluate  the sensitivity
of  the  kit,  26  dengue-positive  CSF  samples  were  used.  The  Pan-E  Dengue  Early  kit  was  able  to detect  theeywords:
engue virus
iagnosis
S1  antigen
erebral spinal ﬂuid
NS1  antigen  in  13  of  26  dengue-positive  CSF  samples,  resulting  in  a  sensitivity  of 50%  (95%  conﬁdence
interval,  29.9–70.1%)  and  speciﬁcity  of  100%  (95%  conﬁdence  interval,  75.3–100%).  The  kit was  able  to
detect  the NS1  antigen  in  CSF  of  individuals  who  had  died  of  dengue.  When  used  in  combination  with
IgM,  the  detection  rate  rose  to 92.3%.  This  study  reports  a  method  for rapidly  detecting  the  dengue  virus
in  CSF,  thereby  increasing  the  diagnosis  of  dengue  fever cases  with  unusual  neurological  manifestations.LISA
Dengue fever is a mosquito-borne disease caused by one of
our dengue viruses (DENV), DENV-1, DENV-2, DENV-3 and DENV-
, which belong to the Flavivirus genus of the Flaviviridae family
Gubler, 2002; ICTV, 2006). Its prevalence has been increasing in
ecent decades. Currently it is endemic in over 100 countries in
frica, the Americas, Eastern Mediterranean, Southeast Asia and
estern Paciﬁc (WHO, 2009).
In Brazil, dengue epidemics have been described since 1986, ini-
ially with involvement of DENV-1, followed by DENV-2 in 1990,
nd DENV-3 after 2000 (Nogueira et al., 2007). In the state of
eará in Northeast Brazil, the disease is endemic and is caused
y serotypes 1, 2 and 3, with cases reported every year and peri-
dic epidemics. The highest number of cases was observed in 1987,
994, 2001 and 2008. In 2003, a severe DENV-3 epidemic occurred,
nd dengue hemorrhagic fever (DHF) incidence was high among
dults (Cavalcanti et al., 2010).Dengue’s symptoms can vary from mild fever, the most
ommon form, to potentially fatal forms, such as dengue DHF
ever and dengue shock syndrome (DSS). Unusual manifesta-
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tions, such as myocardiopathy, hepatic insufﬁciency, fulminant
hepatitis, encephalopathy and encephalitis, have also become com-
mon  (Nogueira et al., 2007). These ﬁndings are due perhaps to
the increase of dengue diagnosis. The involvement of the cen-
tral nervous system (CNS) in dengue patients has been reported
in countries where the disease is endemic. There is no antiviral
therapy or vaccine approved for use against dengue, so patient
management requires good laboratory and clinical support. Spe-
ciﬁc and rapid diagnosis can help directing the proper treatment to
patients (WHO, 2009).
The  DENV has three genes that encode for structural proteins:
envelope (E), membrane (M)  and capsid (C), and seven genes that
encode for non-structural proteins: NS1, NS2A, NS2B, NS3, NS4A,
NS4B and NS5. The glycoprotein NS1 is highly conserved, secreted
by cells infected with DENV in vitro and in vivo, but its biologi-
cal activity is still not well understood. During in vitro infection,
NS1 protein is expressed in a form associated with the intracellu-
lar membrane, which is essential for viral replication, or associated
with the cell surface, which can be involved in signal transduc-
tion (Mackenzie et al., 1996). NS1 protein, in solution, circulates
Open access under the Elsevier OA license.and accumulates in the plasma of patients infected with DENV
throughout the clinical phase, and can be correlated with the
development of more serious forms of the disease (Libraty et al.,
2002).
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Table  1
Detection rate for the methods used to diagnose dengue according to the available samples of patients with DENV infection.
Clinical sample RT-PCRa P/S (%) Virus Isolation Pb/Sc (%) Serotype detected IgMd P/S (%) NS1 Age P/S (%)
CSFg 9/26 3/26 3 DENV-2 19/26 13/26
(34.6) (11.5) 4 DENV-3 (73.1) (50)
2  DENV-1
Blood or serum 2/20 2/26 2 DENV-3 1 4/11 –f
(10.0) (7.7) DENV-1 (36.4)
Total  11/46 5/52 3 DENV-2 23/37 13/26
(23.9)  (9.6) 6 DENV-3 3 DENV-1 (62.2) (50)
a Reverse transcriptase-polymerase chain reaction (RT-PCR).
b Positive (P).
c Studied (S).
d Immunoglobulin M (IgM).
e Non-structural antigen (NS1 Ag).
g
i
s
m
(
r
a
d
i
t
t
d
p
i
a
o
S
d
n
a
s
e
i
1
a
I
a
u
e
a
d
s
s
o
C
v
A
i
t
w
t
a
mental confusion (19.2%); abdominal pain (15.4%); agitation
(11.5%); hemorrhage (11.5%); somnolence (7.7%); splenomegaly
(7.7%); chills (7.7%); cough (7.7%); diarrhea (7.7%); coma (7.7%);
and, at a lower percentage (3.8%), anorexia, abdominal bloating,
Table 2
Diagnostic accuracy score for the NS1 detection by ELISA kit in CSF samples.
Diagnosis Positive Negative Total
Dengue 13 13 26
Non  dengue 0 60 60f Not done (–).
g Cerebral spinal ﬂuid (CSF).
Several new commercial assays for detection of the NS1 anti-
en have been developed. The employment of the enzyme-linked
mmunosorbent assay (ELISA) to detect NS1 protein from DENV in
erum or plasma of patients with acute disease serves as a supple-
entary method for use in association with other diagnostic tests
Dussart et al., 2008; Blacksell et al., 2008). However, there are no
eports of the use of these tests on the cerebro spinal ﬂuid (CSF). This
pplication would be very useful to diagnose cases of non-classical
engue.
The purpose of this study was to evaluate the performance of the
mmunosorbent assay Pan-E Dengue Early ELISA (Panbio Diagnos-
ics, Brisbane, Australia) (NS1 Early), in detecting the presence of
he NS1 antigen (NS1 Ag) in CSF samples obtained during autopsies.
Epidemiological and clinical data were obtained from a national
atabase system that provides information on age and sex of each
atient, CSF collection and the date when symptoms occurred. Clin-
cal data and CSF samples were collected from patients who  died of
 dengue-like illness, and were autopsied at the municipal coroner’s
fﬁce in the context of the dengue surveillance activity of the Ceará
tate Health Secretariat. CSF specimens from people with other
iagnosed diseases (HIV infection, leptospirosis, visceral leishma-
iasis, pneumonia, fungal meningitis, meningococcal meningitis
nd other bacterial forms of meningitis) were used to evaluate the
peciﬁcity of the assay kit. Contamination of CSF with blood was  an
xclusion criterion for the samples.
CSF samples were tested for the presence of DENV by viral
solation in C6/36 cells, as previously described (Gubler et al.,
984); genome detection was by RT-PCR (Lanciotti et al., 1992);
nd IgM detection was by IgM-capture with the Enzyme-Linked
mmunosorbent Assay (ELISA) (Panbio, Brisbane, Australia). All
ssays were conducted according to the manufactures ‘instructions,
sing a 1:2 sample dilution (Soares et al., 2006). Cases were consid-
red positive for DENV infection when CSF samples were positive
ccording to one or more of these tests and patients presented
engue-like syndrome. Cases were considered negative when CSF
amples were negative for all of these tests and were diagnosed as
uffering from another disease.
The study was approved by the ethics and research committee
f São José Infectious Disease Hospital (protocol 005/2009, number
AAE:0005.0.042.000-09).
The NS1 Early system is an antigen-capture ELISA that pro-
ides qualitative, non-serotype-speciﬁc detection of DENV NS1 Ag.
ll tests were performed in accordance with the manufacturers’
nstructions. Brieﬂy, 100 L of diluted (1:2) samples, positive con-
rol, negative control and calibrator were added to microwells that
ere pre-coated with a polyclonal capture anti-NS1 antibody and
hen incubated for 1 h, at 37 ◦C. Each plate was washed six times
nd incubated for 1 h at, 37 ◦C, following the addition of HRP-conjugated anti-NS1 Mab. After six washes, antibody complexes
were detected by adding TMB  and incubating the plate for 10 min
at room temperature. The reaction was stopped by adding a stop
solution, and the plate was read at 450 nm,  with a 630 nm reference
ﬁlter. A sample ratio was determined for each sample by dividing
the average optical density (OD) of the test sample by the aver-
age OD of the cutoff control. Sample ratios of <0.5, 0.5 to <1.0, and
≥1 were indicative of negative, inconclusive and positive results,
respectively. Inconclusive samples were considered negative after
the tests were repeated and remained inconclusive.
To evaluate the performance of the test statistical measures of
sensitivity and speciﬁcity, a conﬁdence interval (CI) of 95% was
used.
CSF samples from 26 patients who  presented fatal dengue
infection and 60 negative for dengue were selected to assess the
performance of the NS1 Early kit. All these 26 positive samples were
positive for dengue in CSF previously by at least one other diagnos-
tic method. The kit showed 73 negative and 13 positive results for
the presence of NS1 Ag. The 13 positive samples were previously
positive for DENV in CSF. The detection rate for the methods used to
diagnose dengue, according to the samples of patients with DENV
infection, is shown in Table 1.
The results of sensitivity and speciﬁcity in relation to the detec-
tion of NS1 Ag in CSF can be seen in Table 2. Two  CSF samples that
gave ambiguous results were retested and considered negative. The
percentage of detection of the NS1 Early test in CSF of patients with
laboratory diagnosis of dengue fever, according to the IgM detec-
tion methodology, is shown in Table 3. The detection rate of the
combination of IgM antibodies and NS1 Ag was 92.3% (Table 4).
In patients with dengue, the average between the onset of symp-
toms to death was six days, ranging from 1 to 14 days. The signs and
symptoms presented were: fever (77%); headache (42.3%); vomit-
ing (30.7%); asthenia (26.9%); myalgia (26.9%); dyspnea (19.2%);Total 13 73 86
Sensitivity 50% (95% CIa-29.9–70.1)
Speciﬁcity 100% (95% CI-94.0–100)
a Conﬁdence interval (CI).
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Table  3
Detection rate of NS1 Ag according to the presence of IgM in 26 CSF samples.
Presence of IgMa Absence of IgM Total
NS1+b 9 4 13
NS1−c 10 3 13
Total 19 7 26
Detection (%) 9/26 (34.6) 4/26 (15.4) 13/26 (50)
a Immunoglobulin M (IgM).
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Db Non-structural 1 antigen positive (NS1+).
c Non-structural 1 antigen negative (NS1−).
imb stiffness, ear infection, cyanosis, nausea, chest pain, pancy-
openia, hypotension, sweating, acute renal failure, septic shock,
ntra-orbital swelling, dizziness, paresthesia, hallucinations and
onvulsion.
Of the 26 dengue patients, 9 had co-morbidities: one had a res-
iratory infection, three had bacterial meningitis, one had Wilson’s
isease, one had infectious enteritis, one had pneumonia, one had
n ear infection and one had a varicella-zoster virus infection. Six
atients were classiﬁed as DHF, one as DSS and the other 19, who
id not meet the World Health Organization criterion for DHF clas-
iﬁcation, were considered as having severe dengue.
The mean age of patients was 27 years, ranging from 2 months
o 84 years, and 26.9% (7/24) of them were younger than 7 years old.
emales accounted for 62.5% of the cases and males for the other
7.5%.
The increasing transmission of the dengue virus continues to be
 global public health problem, especially in developing countries,
here access to preventive and diagnostic resources is limited.
ince the appearance of this virus in Brazil, speciﬁcally in the state
f Ceará, in 1986, the number of serious cases of the disease has
een increasing steadily in line with other tropical and subtropi-
al regions of the world, where the disease has become endemic,
ith cyclical variation: years of substantial epidemics followed by
on-epidemic years (WHO, 2009).
The severe forms of the disease have caused unusual manifesta-
ions of dengue, such as neurological signs. DENV virus, though not
onsidered neurotropic, has been isolated or its viral antigens have
een observed in human CNS (Miagostovich et al., 1997; Ramos
t al., 1998). This also has been demonstrated by viral isolation and
etection of viral RNA in CSF and demonstration of intrathecal syn-
hesis of speciﬁc dengue antibodies (Chen et al., 1991; Nogueira
t al., 2002; Puccioni-Sholer et al., 2009). However, Rosen et al.
1999), could not evidence virus replication in the brain in fatal
uman infections.
The results of this study show that NS1 Ag can be detected in CSF
y using a commercially available kit: NS1 Early, even though this
it was not standardized for testing CSF. There is no kit available
esigned to detect IgM antibodies in CSF either. Instead, this detec-
ion is generally done using a kit with standardized serum. Soares
t al. (2006) found this antibody functioning with CSF in a 1:2 dilu-
ion. However, to detect IgM the patient must have had the disease
or more than ﬁve days, whereas viral antigens can be detected only
uring viremia, thus enabling diagnosis.
able 4
etection of IgM and NS1 Ag in CSF samples.
Test Positive Negative Detection (%)
IgMa 19 7 73.1
NS1b 13 13 50
IgM-NS1 (combined)c 24 2 92.3
a Immunoglobulin M (IgM).
b Non-structural antigen (NS1 Ag).
c IgM and/or NS1 Ag positive (combined).al Methods 177 (2011) 128– 131
NS1 Ag was detected in 50% of the cases where CSF had been
found positive by other methods. The sensitivity of serum NS1 Ag
detection by this kit ranges from 60.4% (Dussart et al., 2008) to
91.6% (Serakan et al., 2007). It is known that the quantity of IgM
in CSF is lower than in serum (Chen et al., 1991; Puccioni-Sholer
et al., 2009). Maybe the same phenomenon occurs in the presence
of NS1 Ag in CSF. Taking into account that there are no published
parameters for comparing this ﬁnding of NS1 Ag in CSF, it should
be considered one more method for the diagnosis of dengue in this
type of material, thus opening the discussion on its applicability in
this type of sample. However, the use of NS1 Ag combined with IgM
detection increased dengue diagnosis in CSF to 92.3%, consistent
with a recent assessment of these two kits in serum reported by
Blacksell et al. (2008).
The speciﬁcity values of 100% for the NS1 Early kit found when
testing CSF were similar to other reports in the literature with the
use of serum (Blacksell et al., 2008; Dussart et al., 2008; Lima et al.,
2010). However, Guzman et al. (2010) found 90% speciﬁcity when
tested in healthy blood donors and patients with other conﬁrmed
diagnoses.
A study using the NS1 Early kit showed that when IgM was
present in the serum, the sensitivity of NS1 Ag detection fell from
91.6% to 48.3% (Serakan et al., 2007). This also happened in the CSF
samples studied here, but despite the average of six days between
the onset of the disease and the sample collection, the detection rate
decreased slightly in relation to the presence of IgM, from 57.1% to
47.4% for the NS1 Early kit. This fact is probably due to the type of
patient, since all the samples were taken from patients with fatal
outcomes. They could have had higher levels of the NS1 glycopro-
tein circulating in the plasma and higher levels of viral RNA, which
could be one of the reasons for the development of serious forms
of the disease, as suggested by Libraty et al. (2002),  even though
many patients with high levels of viremia never develop clinical
complications. However, the severe syndrome has been observed
in patients who  present circulating heterotypic dengue antibodies
at high concentrations (Halstead, 2009).
This evaluation shows that the NS1 Early kit for detection of
NS1 Ag in serum can be used on CSF samples from patients diag-
nosed with dengue. Serological tests are simple, rapid and easy
to perform, but the average lifespan of IgM antibodies, which can
be up to two months, confuses the diagnosis in cases where the
date of disease onset is unknown, leaving questions about whether
the infection is acute or recent (Innis, 1997). The detection of the
NS1 antigen combines the accuracy and speed of RT-PCR with the
practicality of the ELISA technique, providing a reliable result that
facilitates clinical management of patients with neurological man-
ifestations.
The use of tests to detect the NS1 Ag allows studying the involve-
ment of the CNS in patients suspected of being infected with DENV,
enabling better support for patients with severe forms of the dis-
ease. Therefore, the results of this study suggest the use of the
Pan-E Dengue Early ELISA assay to detect viral NS1 Ag in CSF, to
diagnose severe forms of dengue that present neurological man-
ifestations in endemic regions for dengue. However, it should be
used in association with DENV IgM antibody detection in CSF, in
order to increase the sensitivity of the diagnosis. Besides this, more
studies, including during non-epidemic periods and prospective
studies, are needed to assess better the accuracy of the kit on CSF
samples.
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